Wednesday, January 4, 2017

RedHill Biopharma Announces Exercise of Underwriters’ Option

TEL-AVIV, Israel, Jan. 04, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the underwriters of its previously announced underwritten public offering of 2,250,000 American Depository Shares (“ADSs”), each representing 10 of its ordinary shares, and warrants to purchase 1,125,000 ADSs, have partially exercised their option and purchased 133,104 ADSs.


Source : RedHill Biopharma Ltd.

No comments:

Post a Comment